JP2019519544A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519544A5 JP2019519544A5 JP2018564829A JP2018564829A JP2019519544A5 JP 2019519544 A5 JP2019519544 A5 JP 2019519544A5 JP 2018564829 A JP2018564829 A JP 2018564829A JP 2018564829 A JP2018564829 A JP 2018564829A JP 2019519544 A5 JP2019519544 A5 JP 2019519544A5
- Authority
- JP
- Japan
- Prior art keywords
- vedolizumab
- dose
- composition
- responder
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662349026P | 2016-06-12 | 2016-06-12 | |
| US62/349,026 | 2016-06-12 | ||
| PCT/US2017/037072 WO2017218434A1 (en) | 2016-06-12 | 2017-06-12 | Method of treating inflammatory bowel disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019519544A JP2019519544A (ja) | 2019-07-11 |
| JP2019519544A5 true JP2019519544A5 (enExample) | 2020-07-27 |
| JP7202893B2 JP7202893B2 (ja) | 2023-01-12 |
Family
ID=59270123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018564829A Active JP7202893B2 (ja) | 2016-06-12 | 2017-06-12 | 炎症性腸疾患を治療する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11389533B2 (enExample) |
| EP (1) | EP3468597A1 (enExample) |
| JP (1) | JP7202893B2 (enExample) |
| CN (1) | CN109414502A (enExample) |
| CA (1) | CA3027286A1 (enExample) |
| MA (1) | MA45245A (enExample) |
| WO (1) | WO2017218434A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA116189C2 (uk) * | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| EP3581585A1 (en) | 2014-11-26 | 2019-12-18 | Millennium Pharmaceuticals, Inc. | Vedolizumab for the treatment of fistulizing crohn's disease |
| CA3223332A1 (en) * | 2021-06-17 | 2022-12-22 | Prometheus Laboratories Inc. | Systems and methods for improved targeted therapy |
| EP4555323A1 (en) * | 2022-07-13 | 2025-05-21 | Regeneron Pharmaceuticals, Inc. | Mild acid immunoassays for detection of analytes |
| TW202504919A (zh) * | 2023-05-30 | 2025-02-01 | 美商派拉岡醫療公司 | α4β7整合素抗體組合物及使用方法 |
| CN121889424A (zh) | 2023-08-14 | 2026-04-17 | 派拉冈医疗公司 | α4β7整联蛋白结合蛋白及使用方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| JP3095168B2 (ja) | 1988-02-05 | 2000-10-03 | エル． モリソン，シェリー | ドメイン‐変性不変部を有する抗体 |
| JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| WO1996024673A1 (en) | 1995-02-10 | 1996-08-15 | Leukosite, Inc. | Mucosal vascular addressins and uses thereof |
| US7803904B2 (en) | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| US6197582B1 (en) | 1998-03-18 | 2001-03-06 | The Trustees Of Columbia University In The City Of New York | Development of human monoclonal antibodies and uses thereof |
| US20010046496A1 (en) | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
| JPWO2002078779A1 (ja) | 2001-03-27 | 2004-07-22 | 日本ゼオン株式会社 | 医療用ガイドワイヤ |
| WO2006026759A2 (en) | 2004-09-03 | 2006-03-09 | Genentech, Inc. | Humanized anti-beta7 antagonists and uses therefor |
| JP2009515552A (ja) | 2005-11-17 | 2009-04-16 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | α４β７インテグリン反応性ヒト化免疫グロブリン |
| WO2010107752A2 (en) | 2009-03-20 | 2010-09-23 | Amgen Inc. | Alpha-4-beta-7 heterodimer specific antagonist antibody |
| TWI907924B (zh) | 2011-05-02 | 2025-12-11 | 日商武田藥品工業股份有限公司 | 抗-α4β7抗體之調配物 |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| EP3581585A1 (en) | 2014-11-26 | 2019-12-18 | Millennium Pharmaceuticals, Inc. | Vedolizumab for the treatment of fistulizing crohn's disease |
| WO2016105572A1 (en) | 2014-12-24 | 2016-06-30 | Millennium Pharmaceuticals, Inc. | PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-α4β7 INTEGRIN ANTIBODY |
| MA41636A (fr) | 2015-03-06 | 2018-01-09 | Millennium Pharm Inc | Méthode de traitement de la cholangite sclérosante primitive |
| PE20180509A1 (es) | 2015-06-08 | 2018-03-09 | Univ Washington | Composiciones y metodos para tratar la enfermedad celiaca |
| CA3017743A1 (en) | 2016-03-14 | 2017-09-21 | Millennium Pharmaceuticals, Inc. | Method of preventing graft versus host disease |
| EP3430053A1 (en) | 2016-03-14 | 2019-01-23 | Millennium Pharmaceuticals, Inc. | Methods of treating or preventing graft versus host disease |
| EP3433275A1 (en) | 2016-03-24 | 2019-01-30 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments |
| WO2017165742A1 (en) | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments |
| JP7162533B2 (ja) | 2016-05-04 | 2022-10-28 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | 炎症性腸疾患の治療を目的とする三剤併用療法 |
-
2017
- 2017-06-12 CA CA3027286A patent/CA3027286A1/en active Pending
- 2017-06-12 WO PCT/US2017/037072 patent/WO2017218434A1/en not_active Ceased
- 2017-06-12 US US16/309,002 patent/US11389533B2/en active Active
- 2017-06-12 CN CN201780041382.4A patent/CN109414502A/zh active Pending
- 2017-06-12 MA MA045245A patent/MA45245A/fr unknown
- 2017-06-12 EP EP17734895.0A patent/EP3468597A1/en active Pending
- 2017-06-12 JP JP2018564829A patent/JP7202893B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Korean Association for the Study of the Liver (KASL | KASL clinical practice guidelines: management of chronic hepatitis B | |
| Zang et al. | IL-23 production of liver inflammatory macrophages to damaged hepatocytes promotes hepatocellular carcinoma development after chronic hepatitis B virus infection | |
| JP2018503618A5 (enExample) | ||
| JP2022033891A (ja) | 関節リウマチを治療するための組成物およびこれを使用する方法 | |
| US9980960B2 (en) | Methods for determining the risk of cardiovascular disease in a subject having a chronic viral infection | |
| JP2018515493A5 (enExample) | ||
| JP2019505553A (ja) | インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置 | |
| Freedman et al. | Twenty years of subcutaneous interferon-beta-1a for multiple sclerosis: contemporary perspectives | |
| Qin et al. | MALT-1 inhibition attenuates the inflammatory response of ankylosing spondylitis by targeting NF-κB activation | |
| Melica et al. | Primary vasculitis of the central nervous system in patients infected with HIV‐1 in the HAART era | |
| JP7495403B2 (ja) | 巨細胞性動脈炎の治療 | |
| Bascones-Martinez et al. | Oral manifestations of pemphigus vulgaris: clinical presentation, differential diagnosis and management | |
| TWI569808B (zh) | 肝細胞腫瘤（ｈｃｃ）之治療 | |
| JP2023515528A (ja) | ブルトン型チロシンキナーゼの阻害剤を使用する一次性進行型多発性硬化症の治療方法 | |
| Kameda et al. | Development and validation of handy rheumatoid activity score with 38 joints (HRAS38) in rheumatoid arthritis patients receiving infliximab | |
| Stavinoha et al. | Current therapy of chronic liver disease | |
| Das et al. | Unusual and lesser-known rare causes of adult growth hormone deficiency | |
| JP2023052642A (ja) | 抗ｃｄ５２抗体を用いて多発性硬化症を処置するための経路およびスケジュール | |
| US12544392B2 (en) | Treatment of adenovirus infection or disease associated with adenovirus infection | |
| JP2019505598A5 (enExample) | ||
| Hirosawa et al. | No regional disparities in Sofosbuvir Plus Ribavirin Therapy for HCV Genotype 2 infection in Tochigi prefecture and its vicinity | |
| Wan et al. | Effectiveness of tocilizumab without high-dose Glucocorticoids in patients with active Takayasu arteritis: a single center observational study | |
| Tomelleri et al. | Ab0621 gender differences in clinical presentation and vascular pattern in patients with Takayasu arteritis | |
| Rizvi | Disease-Modifying Agents | |
| CA3301059A1 (en) | Treatment of adenovirus infection or disease associated with adenovirus infection |